Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On July 22, 2022, Nasdaq Listing Qualifications Department ("Nasdaq") notified
Lead Edge Growth Opportunities, Ltd (the "Company") that the Company no longer
complies with Nasdaq's independent director requirements as set forth in Listing
Rule 5605. The staff of Nasdaq (the "Staff") determined that the Company's
non-compliance was due to the resignation of Ms. Margaret C. Whitman from the
Company's Board of Directors (the "Board") as of July 15, 2022. The Staff
determined that it is necessary and appropriate for the protection of the
investors to disclose potential delisting proceedings due to non-compliance.
Pursuant to Listing Rule 5605(b)(1)(A), the Staff has provided the Company a
cure period in order to regain compliance as follows: (a) until the earlier of
the Company's next annual shareholders' meeting or July 15, 2023; or (b) if the
next annual shareholders' meeting is held before January 11, 2023, then the
Company must evidence compliance no later than January 11, 2023 (the "Cure
Period"). The Company must submit to Nasdaq documentation, including biographies
of any new directors, evidencing compliance with the rules no later than this
date. In the event the Company does not regain compliance by this date, Nasdaq
rules require Staff to provide written notification to the Company that its
securities will be delisted.
The Company intends to submit required documentation to Nasdaq within the Cure
Period to regain compliance with the Independent Director requirements under the
Nasdaq Listing Rules.
1
© Edgar Online, source Glimpses
LEAD EDGE GROWTH OPPORTUNITIES, LTD 
